MedImmune Ventures appoints Ron Laufer

pharmafile | June 18, 2010 | Appointment | Research and Development AstraZeneca, MedImmune, appointment, research and development 

Ron Laufer has joined MedImmune’s venture capital arm as senior managing director.

The company, which is the worldwide biologics unit for AstraZeneca, said Laufer wold strengthen its long-term commitment to supporting scientific innovation through strategic venture capital investments.

“I am delighted to join MedImmune Ventures at this exciting time in biopharmaceutical research,” said Laufer. “I look forward to building on a successful history and supporting promising products and companies as they pursue our shared commitment to improving patient health.”

Laufer has more than 15 years industry experience, during which he co-founded Lilly Ventures, Eli Lilly and Company’s corporate venture capital fund.

He was also a managing director for healthcare-focused investment firm Visium Asset Management.

Related Content

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial

AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, …

AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial

AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase …

AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment

AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of …

Latest content